These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16355681)

  • 1. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats.
    Lachowicz JL; Post GS; Brodsky E
    J Vet Intern Med; 2005; 19(6):860-4. PubMed ID: 16355681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.
    Candelaria M; Arias-Bonfill D; Chávez-Blanco A; Chanona J; Cantú D; Pérez C; Dueñas-González A
    Int J Gynecol Cancer; 2009 Dec; 19(9):1632-7. PubMed ID: 19955950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
    Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
    Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemia. Q&A highlights.
    Frame D; Sessions J; Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma.
    Vuky J; Isacson C; Fotoohi M; dela Cruz J; Otero H; Picozzi V; Malpass T; Aboulafia D; Jacobs A
    Invest New Drugs; 2006 Jan; 24(1):85-8. PubMed ID: 16380835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal change glomerulopathy in a cat.
    Backlund B; Cianciolo RE; Cook AK; Clubb FJ; Lees GE
    J Feline Med Surg; 2011 Apr; 13(4):291-5. PubMed ID: 21414552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of imatinib treatment of gastrointestinal stromal tumors].
    Eckhardt S; Pápai Z; Bodoky G; Horti J; Tamás K; Nagy T; Orosz Z; Sápi Z; Gödény M; Jakab K; Esik O; Trón L; Besznyák I
    Orv Hetil; 2003 Nov; 144(45):2207-12. PubMed ID: 14686005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
    Cohen MH; Cortazar P; Justice R; Pazdur R
    Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
    Zoubir M; Tursz T; Ménard C; Zitvogel L; Chaput N
    Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):1-7. PubMed ID: 19839938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.